Phase 4 PTSD Trial, Recruiting NCT03642028 Sponsor: VA Office of Research and Development Condition: PTSD
Back to Ptsd

Phase 4 PTSD Trial, Recruiting

NCT03642028
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman between 18 and 75 years old with a history of serving in the U.S. military, can read and understand English, and are able to sign a consent form
  • You have experienced a traumatic event that meets the official definition used to diagnose PTSD
  • You have had PTSD symptoms for more than 3 months, confirmed by a structured assessment, and meet at least a partial PTSD diagnosis
  • You have significant sleep problems, shown by a score above 14 on a standard insomnia questionnaire
  • If you are currently taking certain antidepressants (such as sertraline, fluoxetine, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, desvenlafaxine, or levomilnacipran), your dose has been stable for at least 4 weeks before joining
  • If you are currently in talk therapy, your treatment has been consistent for at least 6 weeks
  • If you are a woman who could become pregnant, you are not currently pregnant, not breastfeeding, not planning to become pregnant during the study, and are using an approved form of birth control (such as the pill, an implant, an injection, a patch, an IUD, or a double-barrier method)
  • Your sleep apnea screening score is below 30 (if you score between 5 and 30, a referral for further evaluation will be provided)

Who may not be able to join:

  • You have been diagnosed with a moderate or severe alcohol or drug use disorder in the last 3 months (mild alcohol or marijuana use may be considered on a case-by-case basis — confirm with trial site)
  • You have had a manic episode or psychosis within the last 5 years
  • You have experienced a new traumatic event within the last 3 months
  • You have had significant thoughts of harming yourself or others, or any suicidal behaviour, in the past 3 months, or your level of risk requires extra support or hospitalisation
  • You have severe untreated sleep apnea (score above 30) and are not consistently using an effective treatment such as a CPAP machine or oral device
  • You have a neurological condition or a body-wide illness that affects how your brain works (confirm with trial site)
  • You have a serious or unstable physical health condition, such as unstable chest pain, a heart attack within the past 6 months, heart failure, persistent low blood pressure, irregular heartbeat, chronic kidney or liver failure, pancreatitis, or severe lung disease
  • You have a history of severe traumatic brain injury
  • You show signs of mild memory or thinking problems based on a standard cognitive test
  • You are pregnant, breastfeeding, or unwilling to use effective birth control during the study (for women)
  • You have narcolepsy (a condition causing sudden episodes of sleep)
  • You have previously had a bad reaction to a sleeping medication
  • You are currently taking benzodiazepines (a type of sedative), the heart medication digoxin, or certain medications that strongly affect how the body processes drugs (called strong CYP3A inhibitors — confirm with trial site)
  • You regularly use substances that slow the brain and nervous system, such as opioids or alcohol, alongside the study medication
  • You are taking certain antifungal, antibiotic, or antiviral medications, or drink grapefruit juice regularly, that could interfere with the study drug (confirm with trial site for a full list)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Sabra S Inslicht, PhD, San Francisco VA Medical Center, San Francisco, CA

Phone: (415) 221-4810

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
30 August 2019
Est. completion
31 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insomnia Severity Index (ISI); Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov